174 related articles for article (PubMed ID: 34963749)
1. Diagnostic biomarkers for pancreatic cancer: An update.
Yang M; Zhang CY
World J Gastroenterol; 2021 Dec; 27(45):7862-7865. PubMed ID: 34963749
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Fong ZV; Winter JM
Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
[TBL] [Abstract][Full Text] [Related]
3. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
4. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma.
Kriz D; Ansari D; Andersson R
Clin Transl Oncol; 2020 Dec; 22(12):2170-2174. PubMed ID: 32447642
[TBL] [Abstract][Full Text] [Related]
5. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
6. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
[TBL] [Abstract][Full Text] [Related]
7. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
8. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
9. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
[TBL] [Abstract][Full Text] [Related]
10. Current and future biomarkers for pancreatic adenocarcinoma.
Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
[TBL] [Abstract][Full Text] [Related]
11. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
12. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?
O'Neill RS; Stoita A
World J Gastroenterol; 2021 Jul; 27(26):4045-4087. PubMed ID: 34326612
[TBL] [Abstract][Full Text] [Related]
14. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
15. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
16. Development and Multiple Validation of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer.
Kim Y; Yeo I; Huh I; Kim J; Han D; Jang JY; Kim Y
Clin Cancer Res; 2021 Apr; 27(8):2236-2245. PubMed ID: 33504556
[TBL] [Abstract][Full Text] [Related]
17. Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options.
Zhang CY; Liu S; Yang M
World J Gastroenterol; 2022 Dec; 28(48):6827-6845. PubMed ID: 36632312
[TBL] [Abstract][Full Text] [Related]
18. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
19. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study.
Kaur S; Smith LM; Patel A; Menning M; Watley DC; Malik SS; Krishn SR; Mallya K; Aithal A; Sasson AR; Johansson SL; Jain M; Singh S; Guha S; Are C; Raimondo M; Hollingsworth MA; Brand RE; Batra SK
Am J Gastroenterol; 2017 Jan; 112(1):172-183. PubMed ID: 27845339
[TBL] [Abstract][Full Text] [Related]
20. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
